Evidence map›Paper›PMID 33399003›Full record

ArticleJournal of the American Heart Association2021

Multicohort Metabolomics Analysis Discloses 9-Decenoylcarnitine to Be Associated With Incident Atrial Fibrillation.

Lars Lind, Samira Salihovic, Johan Sundström, Corey D Broeckling, Patrik K Magnusson, Jessica Prenni, Tove Fall, Johan Ärnlöv

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Genetics, transcriptomics, metagenomics, and metabolomics in the pathogenesis and prediction of atrial fibrillation.European heart journal supplements : journal of the European Society of Cardiology · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Comprehensive metabolomic characterization of atrial fibrillation.Frontiers in cardiovascular medicine · 2022
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Lars LindDepartment of Medical Sciences Uppsala University Uppsala Sweden.
Samira SalihovicDepartment of Medical Sciences Molecular Epidemiology and Science for Life Laboratory Uppsala University Uppsala Sweden.
Johan SundströmDepartment of Medical Sciences Uppsala University Uppsala Sweden.
Corey D BroecklingProteomics and Metabolomics Facility Colorado State University Fort Collins CO.
Patrik K MagnussonDepartment of Medical Epidemiology and Biostatistics (MEB)Karolinska Institutet Stockholm Sweden.
Jessica PrenniDepartment of Horticulture and Landscape Architecture Colorado State University Fort Collins CO.
Tove FallDepartment of Medical Sciences Molecular Epidemiology and Science for Life Laboratory Uppsala University Uppsala Sweden.
Johan ÄrnlövDivision of Family Medicine and Primary Care Department of Neurobiology, Care Sciences and Society Karolinska Institutet Huddinge Sweden.
Uppsala University · SEColorado State University · USDalarna University · SEKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The molecular mechanisms involved in atrial fibrillation are not well known. We used plasma metabolomics to investigate if we could identify novel biomarkers and pathophysiological pathways of incident atrial fibrillation. Methods and Results We identified 200 endogenous metabolites in plasma/serum by nontargeted ultra-performance liquid chromatography coupled to time-of-flight mass spectrometry in 3 independent population-based samples (TwinGene, n=1935, mean age 68, 43% females; PIVUS [Prospective Investigation of the Vasculature in Uppsala Seniors], n=897, mean age 70, 51% females; and ULSAM [Uppsala Longitudinal Study of Adult Men], n=1118, mean age 71, all males), with available data on incident atrial fibrillation during 10 to 12 years of follow-up. A meta-analysis of ULSAM and PIVUS was used as a discovery sample and TwinGene was used for validation. In PIVUS, we also investigated associations between metabolites of interest and echocardiographic indices of myocardial geometry and function. Genome-wide association studies were performed in all 3 cohorts for metabolites of interest. In the meta-analysis of PIVUS and ULSAM with 430 incident cases, 4 metabolites were associated with incident atrial fibrillation at a false discovery rate <5%. Of those, only 9-decenoylcarnitine was associated with incident atrial fibrillation and replicated in the TwinGene sample (288 cases) following adjustment for traditional risk factors (hazard ratio, 1.24 per unit; 95% CI, 1.06-1.45,

Indexed as

CarnitineAgedAtrial FibrillationBiomarkersChromatography, LiquidEchocardiographyFemaleGenome-Wide Association StudyHumansMaleMass SpectrometryMendelian Randomization AnalysisMetabolomicsRisk AssessmentBiomarkersCarnitineatrial fibrillationcarnitineepidemiologygenemetabolomics

Identifiers

PMID33399003
PMCPMC7955307
OpenAlexW3119275146

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.